Spinal Muscular Atrophy
AUSTRALIA INC.

PO Box 4114
Narre Warren South VIC 3805

Phone: 03 9796 5744
Email: reception@smaaustralia.org.au

ABN 82 885 991 569 A0047660D

1 October 2023

PBS LISTING EXPANSION OF EVRYSDI AND ZOLGENSMA

Following the positive recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC) in April and August this year, we are excited to advise that today the Pharmaceutical Benefits Scheme (PBS) listings of:

- **Evrysdi** (Risdiplam) will be expanded to three additional populations including:
  1. Adults diagnosed with SMA with symptoms onset prior to 19 years of age;
  2. Pre-symptomatic babies with one and two copies of the Survival of Motor Neuron 2 (SMN2) gene (previously the age was 2 months); and
  3. Symptomatic Type IIIb/Type IIIc SMA patient.
- **Zolgensma** will be extended for pre-symptomatic babies with three copies of the SMN2 gene.

This is wonderful news for the adult SMA community who now have two treatment options available to them. For pre-symptomatic babies with one and two copies of the SMN2 gene, they now have three treatment options, whilst pre-symptomatic babies with three copies of the SMN2 gene have their first available treatment option.

We are thrilled that the SMA community have access to a greater range of life-changing treatments, and families will be saved the heartbreak of knowing that there is a treatment available but are not able to access it.

If you have any questions, please don't hesitate to email us at smaaa@smaaustralia.org.au.

Yours sincerely,

Julie Cini
Spokesperson

Seona Donald
President

Gavin Old
Vice President